Cancer name Neuroblastoma
Cancer Type NB
Immunotherapy type Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy
Treatment nivolumab
Drugstatus Approved
Drugbank ID DB09035
Checkpoints
Signature Type Cell
Signature MDSCs
Official Symbol NA
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description In detail, the presence of splenic myeloid cells thatexpressed PD-L1 and CSF-1R at high levels was associated withinefficient antitumor immune responses. Next, we validated the results by comparing the frequencies of the immune cells and demonstrated that combination treatment significantly increased splenic T-cell numbers as well as T-cell infiltrationinto tumors, and reduced macrophages and MDSCs and their expression of PD-L1 and CSF-1R in spleens and tumors.
PMID 28123870
Title Regulation of myeloid cells by activated T cells determines the efficacy of PD-2 blockade